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Multiple Less Common Genetic Variants
Explain the Association of the Cholesteryl Ester
Transfer Protein Gene With Coronary Artery Disease
Benjamin D. Horne, PHD, MPH,*† Nicola J. Camp, PHD,†§ Jeffrey L. Anderson, MD, FACC,*‡
Chrissa P. Mower,* Jessica L. Clarke, BS,* Matthew J. Kolek, BS,* John F. Carlquist, PHD,*‡
for the Intermountain Heart Collaborative Study Group
Salt Lake City, Utah
Objectives The objective of this study was to identify associations of the cholesteryl ester transfer protein (CETP) gene with
coronary artery disease (CAD) with tagging (t) single nucleotide polymorphisms (SNPs) chosen to optimally ac-
count for intra-genic variation.
Background The CETP gene plays a critical role in lipoprotein metabolism, but the common and well-studied TaqIB variant is
inconsistently predictive of CAD.
Methods From a deoxyribonucleic acid bank of 10,020 individuals, nondiabetic nonsmoking patients (n  4,811) with
angiographically defined, clinically significant CAD (70% stenosis) or normal coronaries were genotyped for 11
CETP tSNPs. Myocardial infarction (MI) and lipid levels were evaluated as secondary end points.
Results Analysis of single tSNPs, corrected for multiple comparisons (p  0.00485), identified allele 1086A to be as-
sociated with CAD (p  0.0034). Suggestive allelic and significant genotypic associations were found for
631AA (odds ratio [OR]  3.95, p  0.004 vs. CC) and 2389GA (OR  1.21, p  0.003 vs. GG). Haplotype
analysis by linkage disequilibrium (LD) group revealed a CAD association for LD group B (p  0.0025 across
T1086A, C878T, C408T) and near significance for LD group A (p  0.013 across C-631A, MspI,
G2389A). A weak protective trend for TaqIB was eliminated by adjustment for other tSNPs, and haplotype
analyses suggested that TaqIB was simply a marker for other tSNPs or haplotypes. No tSNP or haplotype associ-
ations with MI were found.
Conclusions Multiple, less common SNPs and haplotype variants underlie CETP-related CAD risk, for which the common
TaqIB variant is simply a poor marker. The occurrence of risk-related variants on separate haplotypes suggests
genetic-risk complexity and allelic heterogeneity. (Database Registry of the Intermountain Heart Collaborative
Study; http://clinicaltrials.gov/ct/show/NCT00406185?order1; NCT00406185). (J Am Coll Cardiol 2007;49:
2053–60) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.039a
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4oronary artery disease (CAD) and its clinical manifesta-
ion, myocardial infarction (MI), are etiologically complex,
ith approximately equal contributions from genetic and
nvironmental factors (1,2). The genetic component of
AD is believed to include modest contributions from
ommon genetic variants in multiple genes, but few associ-
rom the *Cardiovascular Department, LDS Hospital, Intermountain Medical
enter, †Genetic Epidemiology Division, Department of Biomedical Informatics,
nd ‡Cardiology Division, Department of Internal Medicine, University of Utah, Salt
ake City, Utah; and §Genetic Research, Intermountain Healthcare, Salt Lake City,
tah. This study was supported by National Institutes of Health grants HL073117
Drs. Camp and Carlquist), CA099844 and CA098364 (Dr. Camp), and HL071878
Drs. Anderson and Carlquist); an American Heart Association fellowship 0415023Y
Dr. Horne); and the Deseret Foundation, Salt Lake City, Utah.l
Manuscript received December 1, 2006; revised manuscript received January 29,
007, accepted February 5, 2007.tions of common single nucleotide polymorphisms (SNPs)
ave been consistently replicated and the genetic basis of
AD remains obscure (3). Inadequate sample size and poor
henotypic and genetic characterization undoubtedly have
ontributed to this dilemma. Also, the unexpected finding
hat multiple less common, non-synonymous variants (i.e.,
or PCSK-9, ABCA1, APOA1, and LCAT) explain a
ajor portion of population variance of low-density li-
oprotein (LDL) or high-density lipoprotein (HDL) has
hallenged the “common disease, common variant” hypoth-
sis (4,5).
The 22-kilobase cholesteryl ester transfer protein
CETP) gene, located on chromosome 16q21, specifies a
93 amino acid protein, expressed in multiple tissues, that
ocalizes in the circulation primarily on larger, lipoprotein-
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(C) particles, where its princi-
pal role is to catalyze the ex-
change of triglycerides (TG) on
apoB-containing particles (e.g.,
LDL-C, very LDL-C) for cho-
lesteryl esters from HDL-C (6).
Higher CETP concentrations
typically are associated with
lower HDL-C (7,8). TaqIB and
other variants of CETP have
been associated with reduced
CETP activity. However, despite
the consistent association these
variants have with higher HDL-C
levels, their clinical phenotype re-
mains uncertain (9). The previous
postulate that CETP activity is
inversely related to CAD risk (10–
15) has been challenged by the
recent, unexpected finding that
pharmacological inhibition of
CETP (16) increases cardiovascu-
lar risk (17).
Given the critical role of CETP
in reverse cholesterol transport
nd hence potentially in CAD risk, this study comprehen-
ively evaluated CETP genetic variation via SNPs and SNP
aplotypes in a large, angiographically phenotyped patient
ohort. The goal was to better define CETP genotype-
henotype associations and optimally capture both common
nd uncommon genetic variation (18,19) with a recently
escribed set of tagging (t) SNPs (20).
ethods
tudy population. The study population included patients
ndergoing coronary angiography at hospitals within the
tah-based Intermountain Healthcare system who con-
ented to participate in the cardiac catheterization registry of
he Intermountain Heart Collaborative Study. Between
ugust 1994 and June 2004, a cohort of 10,020 patients
men and women) underwent angiography and were en-
olled in the registry. The study was approved by the LDS
ospital’s Institutional Review Board.
ssessment of CAD. The presence of CAD, the primary
tudy end point, was determined by standard coronary
ngiographic procedures. The patient’s angiogram was
raded by a cardiologist (who was unaware of genetic test
esults). Patients were categorized as being free of CAD
i.e., free of CAD or with minimal, 10% stenosis), having
oderate CAD (i.e., most severe lesion 10% to 69%
tenosis), or having significant CAD (i.e., 1 lesion of
70% stenosis). Moderate CAD was classified as an inde-
erminate phenotype and patients in that group were ex-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CETP  cholesteryl ester
transfer protein
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
HDL-C  high-density
lipoprotein cholesterol
LD  linkage disequilibrium
LDL-C  low-density
lipoprotein cholesterol
MAF  minor allele
frequency
MI  myocardial infarction
OR  odds ratio
SNP  single nucleotide
polymorphism
TC  total cholesterol
TG  triglyceride
tSNP  tagging single
nucleotide polymorphismluded from statistical analyses. Because it is the most 7linically relevant phenotype and the decision to treat is
ased on the presence of flow-limiting lesions (i.e., 70%
tenosis), CAD presence was defined as those with signif-
cant CAD, and non-CAD control subjects were those
atients free of CAD.
econdary end points. The secondary end point of MI was
efined as any MI in the patient’s prior history or on
ospital admission. The MI events were determined from
ntermountain Healthcare’s electronic record repository and
ere ruled-in by electrocardiography and/or biomarker
easurements. An MI was defined by biomarkers as a
reatine kinase-myocardial band (CK-MB) 6 mg/dl and a
K-MB index 3% in the appropriate clinical setting. For
I association analyses, the subgroup of patients with
oderate CAD was included.
Lipid measurements were also evaluated as secondary end
oints. Total cholesterol (TC) and TG were measured from
asting blood samples drawn during hospital stay but before
ngiography with dry-slide technology on a VITROS 950
nalyzer (Ortho Clinical Diagnostics, Raritan, New Jersey).
he HDL-C was measured after sample treatment with
ITROS HDL-Cholesterol Magnetic Reagent. The
DL-C was calculated from those values.
linical information. Demographic and health history
ata were obtained from physicians and hospital records and
tored in a research database. These data included age,
ender, smoking status, hypertension, hyperlipidemia, dia-
etes, and family history of early CAD or MI. Smoking was
onsidered present for active smokers or those with a 10
ack-year history. Prevalent diabetes mellitus, hyperlipid-
mia, and hypertension were physician-reported from clin-
cal and laboratory findings or were based on current use of
elevant medications. For laboratory findings, diabetes was
efined as a fasting blood sugar 126 mg/dl, hypertension
s systolic blood pressure 140 mm Hg or diastolic blood
ressure 90 mm Hg, and hyperlipidemia as fasting TC
200 mg/dl or LDL-C 130 mg/dl. Patient-reported
amily history was positive if a first-order relative had
uffered cardiovascular death, MI, or coronary revascular-
zation before age 65 years.
enotyping. Previously, sequence variation in the CETP
ene was determined among 50 unrelated individuals in the
romoter, 16 exons, exon-intron boundaries, and 3= un-
ranslated region (20). From 32 SNPs, 11 tSNPs were
elected from 7 linkage disequilibrium (LD) groups (20)
ith an analysis method that evaluated inferred haplotypes
rom 339 unrelated individuals (19). Those 11 tSNPs were
ncluded in this study. Haplotypes were determined from
hese tSNPs as discussed in the next section.
Genotyping of rs1800776 (C-631A) and rs11076175
MspI) was performed with Simple Probe chemistry and
elt curve analysis on the Light Typer (Roche Diagnostics,
ndianapolis, Indiana). The other tSNPs were genotyped
ith 5= exonuclease (Taqman) chemistry on the ABI Prism
000 (Applied Biosystems, Foster City, California). Assay
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erminator chemistry.
tudy hypothesis and design. The primary study hypoth-
sis was that 1 or more of the 11 tSNPs or a tSNP-defined
aplotype would predict an altered risk of angiographic
AD. Secondary end points of interest were MI and lipid
evels (e.g., HDL-C). Study patients were separated a priori
nto three mutually exclusive groups, with the primary study
opulation being nondiabetic, nonsmoking patients. To
educe unwanted variation from non-cholesterol genetic and
nvironmental factors, diabetic patients and smokers were
xcluded from the primary analysis and evaluated as second-
ry study populations as: 1) any smoker, and 2) nonsmoking
iabetic patients (mutually exclusive). Analysis was re-
tricted to those patients with complete genotypic data for
ll 11 tSNPs.
tatistical considerations. Differences in CAD diagnosis
nd MI were evaluated for each tSNP by the chi-square test.
ultivariable logistic regression provided adjusted odds
atios (ORs) and 95% confidence intervals (CIs) after forced
ntry of covariables (age, gender, cardiac risk factors).
djustment also was made in other models for TC,
DL-C, HDL-C, TG, and self-reported ethnicity. Evalu-
tion of tSNP associations with lipid levels was performed
y Student t test (TG level was log-transformed first).
Haplotype-defining tSNP groups were assigned a priori
n the basis of prior LD group findings (20). Inference of
hased haplotypes and comparison of haplotype frequency
ifferences between patients with and without CAD or MI
as performed with SimHap and on the basis of 1,000
imulations. Haplotypes of frequency 0.01 that contained
variant allele were compared with the LD group’s wild-
ype haplotype. Extended haplotypes with tSNPs from
ultiple LD groups were then evaluated to find the best
AD risk-discriminating haplotypes. Haplotype analyses
id not employ multivariable adjustment, owing to software
Overall Population Baseline Characteristics for tand the Two Second ry Study Populat ons Amon
Table 1 Overall Population Baseline Characand the Two Secondary Study Popu
Characteristic
Primary Population
Nonsmoking Nondiabetic Pat
(n  4,811)*
CAD cases 67%
Age, yrs (mean  SD) 63  13
Gender (male) 64%
Hypertension 54%
Hyperlipidemia 49%
Family history 37%
Diabetes 0%
Smoking 0%
Ethnicity
Caucasian 90%
Non-Caucasian 4%
Unknown 6%
*These sample sizes are for the primary end point of coronary artery di
with an indeterminate CAD phenotype were included, sample sizes were in
patients, n  1,637 (MI cases: 37%) for smokers, and n  1,430 (MI cases:estrictions. Finally, association analyses were performed at
he patient level to obtain ORs for the best haplotypes on
he basis of carriage of 0, 1, or 2 copies of the haplotype
ignoring phase uncertainty).
Pair-wise LD was calculated and plotted with Haploview.
ther statistical analyses were performed with SPSS (ver-
ion 13.0; SPSS Inc., Chicago, Illinois). Two-tailed p values
ere designated as significant for p  0.00485 on the basis
f correction for multiple comparisons of the 11 tSNPs (20)
nd were considered suggestively associated for p  0.05.
esults
f the 10,020 available patients, a total of 9,692 had a
ufficient quantity of deoxyribonucleic acid to be consid-
red for this study. Of these, 8,382 patients (86%) had
ull genotypic data available. Sixty-seven percent of
atients had CAD. Patient risk factors and ethnicity are
hown in Table 1. Each traditional risk factor predicted
AD at p  0.001.
enetic associations in the primary population (non-
moking, nondiabetic patients). Of the 6,190 nondia-
etic, nonsmoking patients, 4,811 were included (666
ere excluded owing to the moderate CAD phenotype
nd 713 owing to missing 1 genotype). Pair-wise LD
etween the 11 tSNPs is shown in Figure 1. Various tSNP
ssociations with TC, LDL-C, HDL-C, and TG were
ound (Table 2).
Single tSNP analyses (Table 3) identified a significant
llelic association with CAD for tSNP T1086A (p 
.0034). An additive genetic model was suggested (OR 
.84 for TA and OR  0.64 for AA, vs. TT. See online
able 1 for details). In addition, the tSNPs C-631A and
2389A had suggestive allelic associations (Table 3) with
ignificance for the genotype comparisons 631AA vs. CC
OR  3.95, p  0.004) and 2389GA vs. GG (OR 
rimary Study Populationtients With CAD or N CAD
ics for the Primary Study Population
s Among Patients With CAD or No CAD
Secondary Populations
Smokers
(n  1,460)*
Nonsmoking Diabetic Patients
(n  1,270)*
82% 84%
61  11 64  12
78% 60%
61% 80%
63% 73%
47% 48%
20% 100%
100% 0%
87% 89%
5% 5%
8% 6%
CAD). For the end point of myocardial infarction (MI), wherein patientshe Pg Pa
terist
lation
ients
sease (
creased to n  5,477 (MI cases: 30%) for nonsmoking nondiabetic
35%) for nonsmoking diabetic patients.
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yperlipidemia, and family history left no associations at
 0.00485 (T1086A: adjusted p  0.042), primarily
wing to age, but the small changes in the beta-coefficients
uggested a lack of strong confounding and a potential loss
f precision due to addition of terms to the model. Inter-
stingly, despite the biologic plausibility of a confounding
ffect, adjustment for hyperlipidemia and for TC, LDL-C,
DL-C, or TG did not confound tSNP associations nor
id adjustment or stratification by ethnicity (data not
hown).
In haplotype analyses, significant CAD differences were
ound in LD group B (Table 4) for the haplotype ATC (p
.0017 vs. wild-type TCC) across tSNPs T1086A,
878T, and C408T, with OR  0.85 and OR  0.60
or carriage of 1 or 2 ATC haplotypes, respectively. Sug-
estive CAD significance was found for LD group A
haplotype AAA of tSNPs C–631A, MspI, and G2389A,
 0.013 vs. wild-type; OR  1.17 and OR  2.78 for
arriage of one or two copies, respectively) and LD group C
AG haplotype of tSNPs T1086A and NlaIII, p  0.011
s. wild-type; OR 0.83 and OR 0.70 for carriage of one
r two copies, respectively). Haplotypes ATC (LD group B)
nd AAA (LD group A) showed independent associations
data not shown). Haplotype analysis combining tSNPs
rom LD groups A and B resulted in a 6-tSNP haplotype
herein the variants from the CAD-associated haplotypes
reviously mentioned were mutually exclusive, and the
Figure 1 LD Structure of the 11 CETP tSNPs (Heat Map)
Level of linkage disequilibrium (LD) (r 2 value) is displayed within the shaded diam
CETP  cholesteryl ester transfer protein; tSNP  tagging single nucleotide polym-tSNP haplotype associations were of similar or weaker aignificance (data not shown), suggesting independence of
ffect for LD groups A and B.
The LD group C haplotype AG was associated with
igher HDL-C (mean 54.2 [AG variant] vs. 50.9 mg/dl
wild-type], p  0.0016), as were LD group B haplotype
TC (53.6 vs. 50.3 mg/dl, respectively, p  0.0086) and
D group D haplotype AC (52.9 vs. 50.7 mg/dl, p 
.023). The LD group C haplotype TA was weakly asso-
iated with LDL-C (mean 102 vs. 105 mg/dl, p  0.014).
ole of TaqIB. Both allelic (Table 3) and genotypic (AA
B2B2] vs. GG [B1B1]: OR  0.86, p  0.08) analysis
howed a weak association of tSNP TaqIB with CAD. The
ssociation was moderately reduced by adjustment for tra-
itional risk factors (p  0.12) and eliminated by adjust-
ent for tSNPs C–631A, MspI, T1086A, C878T,
2389A, and C408T (OR  1.04, p  0.74). In the
D group D haplotype to which TaqIB belongs, some
otential associations were suggested, but the evidence was
pread across multiple haplotypes (Table 4). Haplotypes
cross LD groups A, B, and D were considered (i.e., by
dding TaqIB to the 6 tSNPs previously mentioned), but
his did not increase the discriminatory power of any
aplotype. Instead, the CAD association evidence for the
-tSNP CAATGC haplotype from LD groups A and B
as split between two 7-tSNP haplotypes (data not shown).
ssociation with MI. Thirty percent of patients had ex-
erienced an MI (Table 1). No single tSNP was associated
ith MI after correction for multiple tests (online Table 2),
m.
onds.
orphisnd no haplotype was associated with MI (online Table 3).
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May 22, 2007:2053–60 CETP tSNPs, tSNP Haplotypes, and Clinical CAD Riskonsmoking diabetic patients. Of the 1,592 nonsmoking
iabetic patients (not studied in the preceding text), 1,270
ere included in this secondary analysis (160 were excluded
wing to moderate CAD and 162 owing to missing geno-
ypic data). Gender (p  0.009), hypertension (p  0.001),
yperlipidemia (p  0.001), and family history (p  0.001)
ere all different compared with nonsmoking nondiabetic
atients. No significant tSNP or haplotype associations were
ound among diabetic patients (see online Tables 4 to 7).
mokers. Of the 1,910 smokers not studied in the primary
nalysis, 1,460 were included in secondary analysis (177
ere excluded owing to moderate CAD and 273 owing to
issing genotypes). Smokers were younger (61 vs. 63 years,
 0.036) and more likely (p 0.001) to be male and have
AD, hypertension, hyperlipidemia, and family history.
nly A1825C was CAD-associated (see online Tables 8
o 11), and when pooled with the primary population, an
nteraction of smoking with A1825C was suggested (test
Average (SD) TC, LDL-C, HDL-C, and TG Levels
Table 2 Average (SD) TC, LDL-C, HDL-C, a
tSNP TC (mg/dl)
rs1800776 (C-631A)
C 181 44
A 181 47
rs708272 (TaqIB: G¡A)
G 180 45
A 182 44
rs11076175 (MspI: A¡G)
A 181 44
G 180 45
rs5883 (F287F: C¡T)
C 181 44
T 181 46
rs289715 (T1086A)
T 180 44
A 183 44
rs289719 (C878T)
C 181 45
T 181 44
rs291044 (G2389A)
G 181 45
A 180 43
rs5880 (A373P: G¡C)
G 181 45
C 175 42*
rs1800774 (C408T)
C 181 44
T 181 46
rs1801706 (NlaIII: G¡A)
G 181 44
A 179 44
rs289745 (A1825C)
A 181 44
C 180 45
*p  0.05; †p  0.00485.
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density
tagging single nucleotide polymorphism.f interaction: p  0.001). iiscussion
ummary of findings. Among a large population of non-
iabetic non-smokers at risk for CAD, the tSNPs
1086A, C-631A, and G2389A of CETP showed
llelic and genotypic associations with angiographic CAD.
urthermore, the haplotype defined by tSNPs 1086A,
878T, and 408C was associated with lower CAD risk,
nd an independent association with higher CAD risk was
uggested for the haplotype defined by631A, MspIA, and
2389A. These findings suggest the presence of two
irectionally different causal variants within or near the
ETP gene and on separate haplotypes. They also suggest
hat CETP genetic risk is complex and characterized by
llelic heterogeneity.
Adjustment for traditional risk factors diminished some
f the genetic associations. However, because genotype
present since conception) predates the appearance of clin-
SNP Allele Carriage
Levels by tSNP Allele Carriage
(mg/dl) HDL-C (mg/dl) TG (mg/dl)
 37 52.1 31.4 162 113
 36 50.3 29.1 171 158
 37 51.3 30.8 165 123
 36 52.8 31.8* 161 109
 37 52.2 31.3 162 114
 36 50.7 30.9 167 131
 37 51.8 31.2 163 117
 39 53.2 32.3 164 117
 37 51.5 31.1 163 118
 36 54.7 32.1† 163 111
 37 51.4 31.0 164 123
 37 53.1 31.8* 161 103
 36 52.1 31.5 163 115
 37 51.7 30.8 163 121
 37 52.1 31.3 163 117
 34 48.7 30.4* 167 121
 37 52.1 31.3 162 114
 37 51.6 31.2 164 122
 37 51.9 31.1 164 120
 37* 52.1 31.8 159 99
 37 52.0 31.4 164 114
 36 51.8 31.1 162 122
tein cholesterol; TC  total cholesterol; TG  triglycerides; tSNP by t
nd TG
LDL-C
105
106
105
104
105
105
105
103
105
106
105
104
104
106
105
101
105
105
105
102
105
104cal risk factors, it can be argued that unadjusted genetic risk
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CETP tSNPs, tSNP Haplotypes, and Clinical CAD Risk May 22, 2007:2053–60ight be more relevant to pathophysiological considerations
i.e., with genes potentially explaining risk factors rather
han the reverse). In contrast, TC, LDL-C, HDL-C, and
G concentrations did not affect tSNP associations, al-
hough several tSNP associations with lipid levels were
ound. Thus, some of the CETP tSNP effects might relate
o mechanisms beyond lipid concentrations, including li-
oprotein functionality.
ationale for elucidating genetic associations. Elucida-
ion of the genetic underpinnings of CAD is of major
cientific interest because: 1) it can provide crucial insights
nto disease pathogenesis; 2) it might be applied to individ-
al risk prediction (“individualized medicine”); 3) it can
timulate the discovery of therapeutic interventions (i.e.,
uiding interventions directed at specific genes, gene prod-
cts, or pathways); and 4) it underlies the pharmacogenetics
f individual patient-drug interactions (3,21).
A logical approach to the discovery of genetic factors for
AD is to focus on genes in biologic pathways implicated in
isease pathophysiology (3,22). Topol et al. (22) divided
hese into four over-arching (and interdependent) pathways:
ipid metabolism, arterial inflammation, endothelial integ-
ity, and thrombosis. The CETP gene represents a critical
lement in the lipid metabolic pathway; hence, understand-
ng its potential contribution to genetic risk is crucial.
owever, despite the consistent association of CETP vari-
nts (including the common and well-studied TaqIB) with
DL-C levels, their impact on CAD end points remains
bscure (9,23). Adding to the uncertainty about CETP ’s
ole in CAD risk is the recent unexpected observation that
harmacological inhibition of CETP (i.e., with torcetrapib)
16) increases cardiovascular risk (17), whereas CETP
ctivity previously had been postulated to be inversely
elated to CAD risk (10–15).
easons for past failures. A number of reasons have been
omparison of tSNP Allelesetween CAD Case and Non-CADntrol Patients in the Primary Study Population
Table 3
Comparison of tSNP Alleles
Between CAD Case and Non-CAD
Control Patients in the Primary Study Population
tSNP (Alleles) MAF Among Controls p Value*
Allelic Odds Ratio
(95% CI)
C-631A A: 0.07 0.008 1.24 (1.06–1.46)
TaqIB (G/A) A: 0.44 0.12 0.93 (0.86–1.02)
MspI (A/G) G: 0.18 0.72 1.02 (0.91–1.14)
F287F (C/T) T: 0.06 0.87 0.98 (0.82–1.18)
T1086A A: 0.14 0.0034 0.83 (0.73–0.94)
C878T T: 0.31 0.21 0.94 (0.86–1.03)
G2389A A: 0.33 0.018 1.12 (1.02–1.22)
A373P (G/C) C: 0.05 0.17 1.14 (0.93–1.38)
C408T T: 0.38 0.25 0.95 (0.87–1.04)
NlaIII (G/A) A: 0.16 0.37 1.05 (0.94–1.18)
A1825C C: 0.39 0.83 0.99 (0.91–1.08)
Chi-square test of allelic association (significance after correction for multiple comparisons: p 
.00485).
CAD coronary artery disease; CI confidence interval; MAFminor allele frequency; tSNP
agging single nucleotide polymorphism.roposed for the frequent failure to replicate SNP associa-
cions (24,25). One is the testing for associations in ade-
uately large samples so as to minimize both Type I (false
ositive) and Type II (false negative) errors. A second
roblem is inadequate characterization and standardization
f study populations, including imperfect ascertainment of
linical phenotypes, mixed genetic background of patients
e.g., population stratification), and evaluation of differing
utcomes (i.e., CAD vs. MI). Another is a failure to address
he problem of multiple comparisons with prospective,
estrictive testing with adequate statistical correction. Still
nother source of complexity is the frequent dissociation of
ntermediate biomarkers (i.e., lipids/lipoproteins) and clin-
cal outcomes (angiographic CAD or MI) (9,23,26).
In addition, a tested SNP might not be biologically
unctional but a marker of a functional variant in some but
ot other populations (18,19). Notably, CETP promoter
NP C-629A (and many other promoter SNPs) is in high
D with TaqIB (20,27). Furthermore, tSNP C878T is in
lmost exact LD with exonic SNP I405V, whereas tSNP
1086A resides on a subset of haplotypes containing
hose and 6 other SNPs (20). When functional SNPs are
nknown, tests of variants in LD groups (i.e., clusters of
ariants that are linked/co-inherited) might more reliably
haracterize susceptibility (19,28).
Finally, the basic assumption in previous studies of
common disease, common variants” might not be generally
orrect. This hypothesis (29) implies that only very common
roportion of Common (Frequency > 0.01)apl types and Ass ciation to CAD forhe LD Groups Contai ing More Than 1 tSNP
Table 4
Proportion of Common (Frequency > 0.01)
Haplotypes and Association to CAD for
the LD Groups Containing More Than 1 tSNP
Haplotype
Proportion in
Control Subjects
*Haplotypic Test
Odds Ratio (95% CI)
LD group A: C-631A, MspI, G2389A
CAG† 50% 1.0
CAA 24% 1.12 (1.01–1.24)
CGG 16% 1.06 (0.93–1.21)
AAA 6% 1.26 (1.06–1.51)
CGA 2% 1.08 (0.87–1.34)
AAG 1% 1.25 (0.87–1.79)
LD group B: T1086A, C878T, C408T
TCC† 32% 1.0
TCT 36% 0.90 (0.81–1.00)
TTC 17% 0.98 (0.86–1.11)
ATC 14% 0.80 (0.69–0.92)‡
TTT 1% 0.82 (0.48–1.38)
LD group C: T1086A, NlaIII
TG† 70% 1.0
TA 16% 1.03 (0.91–1.15)
AG 14% 0.85 (0.75–0.96)
LD group D: TaqIB, C408T
GC† 43% 1.0
AT 24% 0.92 (0.82–1.03)
AC 20% 0.92 (0.82–1.02)
GT 13% 0.91 (0.81–1.04)
Comparison is to the wild-type haplotype; †wild-type haplotype; ‡p  0.0017 (significance after
orrection for multiple comparisons: p  0.00485).
CAD  coronary artery disease; CI  confidence interval; LD  linkage disequilibrium.
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eed be considered (30). However, less frequent, common
but not rare) genetic variants (i.e., MAF  0.01 to 0.20)
lso might exert substantial susceptibility (31) for CAD and
I through the mechanisms of allelic (32) and locus
eterogeneity. Indeed, multiple less common, non-
ynonymous variants in PCSK-9, ABCA1, APOA1, and
CAT have recently been reported to explain a major
ortion of population variance of LDL-C or HDL-C,
urther challenging the common disease, common variant
ypothesis (4,5).
resent rationale. This study was designed to address
everal weaknesses of previous SNP association studies. The
tudy was large, providing power to discover modest risk
ssociations and reduce error. Sources of statistical noise
e.g., smoking) were excluded. Multiple comparisons were
ddressed by appropriate statistical correction. Relevant
linical end points (angiographic CAD, clinical MI) rather
han biomarkers (lipids) were assessed and tested separately.
he SNPs were selected from a comprehensive study (20) so
s to maximally account for genetic variation in CETP.
Together, testing of single tSNPs and of haplotypes can
e complementary. If single tSNPs are themselves disease-
ssociated, they could represent the most powerful disease
arkers (33). In contrast, if they are not and/or if several
unctional SNPs exist in close proximity and interact, then
aplotypes could represent superior markers (28). This
tudy tested for both, with tSNPs as an appealing set of
arkers to address the first argument and haplotypes of
SNPs to address the latter. Finally, our study size allowed
s to address possible associations of less common as well as
he more common CETP polymorphisms with CAD and
I risk.
mplications of study findings. Similar to several other
ipid-metabolic genes (4,5), multiple less common CETP
ariants (MAF  0.01 to 0.20) were associated herein with
AD risk (e.g., C-631A and T1086A). This finding,
aken together with the previous examples, indicates that
he “common variant common disease” hypothesis does not
lways hold and should not be assumed. Because SNPs with
ower MAF necessarily require greater power to detect
ssociations than very common SNPs, candidate gene
tudies should be much larger than previously envisioned
i.e., powered to adequately evaluate MAFs of 0.01 to
.20). Although they require replication and extension,
hese findings revise the understanding of CETP with
espect to CAD pathogenesis, therapeutic insights, indi-
idual risk predictions, and, eventually, individualized
harmacogenetics.
aqIB and the present study. The CETP TaqIB has been
valuated extensively with varied results (e.g., see references
,8,10–12,34,35) and a modest overall association in meta-
nalysis (15). In the present study, an apparent TaqIB
ssociation with CAD (genotypic OR  0.86, p  0.08) of
imilar magnitude to prior reports (15) was eliminated by
djustment for other tSNPs. The confounding of TaqIB
Eesulted primarily because the minor alleles of two tSNPs
ssociated with CAD (C-631A, G2389A) were not on
he haplotypes containing the protective TaqIB variant
llele and because the variant alleles of the tSNPs associated
ith lower CAD risk (T1086A, C878T) were coinci-
ent with the TaqIB variant. This suggests that previous
aqIB associations likely arose as a result of multiple other
ETP variants that are in LD with TaqIB. Thus, TaqIB is
less precise marker of CAD risk than the combination of
ultiple other less common CETP SNPs and should be
eplaced by these markers in future studies.
tudy limitations. Not all CETP SNPs might be “tagged”
y the 11 tSNPs, although they were selected to optimally
ccount for genetic variation in coding and functional
egions. Observational studies are subject to potential selec-
ion bias, and registry patients were at higher CAD risk
han the general population. However, important potential
onfounders were dealt with by design (smoking and dia-
etes) or by multivariable adjustment (for other risk factors).
he study consisted primarily of Caucasians, and the results
ight not apply equally to other ancestral groups. The
unctional effect of tSNP alleles was not directly assessed,
ut associations with lipid levels might be an indirect
arker of functional activity (also, LD group B tSNPs are in
D with I405V and TaqIB [20], which decrease CETP
ass [7,34]; MspI in LD group A might increase mass
7,34]).
onclusions
ultiple, less common CETP tSNPs and tSNP-defined
aplotypes were associated with angiographically defined
AD, thus the association of CETP with CAD might
perate through allelic heterogeneity or haplotype-specific
echanisms. The protective effect previously reported for
aqIB was fully accounted for by other tSNPs, suggesting
hat TaqIB might imperfectly mark the risk carried by
ultiple less-frequent CETP variants. The study also illus-
rates that comprehensive candidate gene evaluations using
SNPs or tSNP haplotypes might explain previously re-
orted associations; this approach should be applied to other
isk-associated genes. Although these findings should be
ndependently validated, they mark an advance in under-
tanding CETP-related pathophysiology and CAD risk.
inally, CETP tSNPs should be combined with those of
ther lipid metabolism genes and, subsequently, genes in
ther atherosclerosis pathways to build a comprehensive
stimate of CAD genetic risk (36).
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